EPITARGET
EPITARGET
EPITARGET

Partner 5 - Istituto di Ricerche Farmacologiche Mario Negri

Istituto di Ricerche Farmacologiche Mario Negri

Dr Annamaria Vezzani

Principal Investigator

Phone: +39 0239014410

Fax: +39 023546277

undefinedE-Mail

 

undefinedPubMed

undefinedResearchGate

 

 

Istituto di Ricerche Farmacologiche Mario Negri

Via Giuseppe La Masa 19

20156 Milano

Italy

undefinedWebsite

EPITARGET Team IRFMN

Teresa Ravizza, PhD

Senior researcher; histology and immunohistochemical studies for quantitative analysis of inflammatory molecules in brain

Phone: +39 02 39014739

Fax: +39 02 3546277

undefinedE-Mail

Silvia Balosso, PhD

Senior researcher; in vivo pharmacology, specimens collection for biomarker analysis

Phone: +39 02 39014739

Fax: +39 02 3546277

undefinedE-Mail

Massimo Rizzi, PhD

Senior researcher; EEG tracing analysis, seizure quantification and biochemical methods (western blot, ELISA)

Phone: +39 02 39014214

Fax: +39 02 3546277

undefinedE-Mail

Dr. Chrysaugi Kostoula

PhD student; in vivo pharmacology

Phone: +39 02 39014739

Fax: +39 02 3546277

undefinedE-Mail

The EPITARGET team from IRFMN
EPITARGET Team IRFMN

Institute presentation

Dr Annamaria Vezzani has a long standing experience in translational research in epilepsy. Her laboratory has a specific interest and expertise in characterisation of seizure generation mechanisms in rodent epilepsy models using biochemical, immunohistochemical and electrophysiological (video/EEG monitoring) techniques. The laboratory exploits the knowledge on seizure mechanisms for preclinical development of novel treatments for patients with drug resistant seizures. Dr Vezzani is a leading scientist in establishing the role of inflammatory molecules in the pathogenesis of seizures since she was the first one to characterize the contributing role of specific inflammatory pathways in seizure mechanisms, namely the IL-1 and Toll-like receptor signalling. She has a long-standing experience in neuropharmacology applied to animal models of epilepsy for studying biologicals and xenobiotics effects on ictogenesis and epileptogenesis.

undefinedOne phase 2b clinical trial is ongoing in drug resistant epilepsy patients using an antiinflammatory drug preclinically developed in Dr Vezzani’s laboratory.

Dr Vezzani was partner in 3 epilepsy oriented EU funded projects (QLG-1999-0098; FP6 Epicure, FP7 NeuroGlia) and was an advisory board member in FP7 Euripides. She is presently in the SAB of a currently funded FP7 project, EPISTOP. She is co-investigator in two running P20 NIH grants (RFA-NS- 12006) oriented to find epilepsy biomarkers.

EPITARGET Team

EPITARGET Consortium
 

EPITARGET Workpackages

EPITARGET Workpackages

Home
Menu
Search
Top

Newsletter Subscription

Please fill in the information of your subscription.

 

You have already subscribed to Newsletter Recipients and wish to update or terminate your subscription? Click here!

News Section

ARTTIC joins EPITARGET Read more

Social Media

Facebook EPITARGET
Home
Menu
Search
Top